NASDAQ: FHTX - Foghorn Therapeutics Inc.

Yield per half year: -55.73%
Dividend yield: 0.00%
Sector: Healthcare

Share chart Foghorn Therapeutics Inc.

Extended chart Simple chart
Financial Markets by TradingView

About Foghorn Therapeutics Inc.

Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system.

more details
It develops FHD-286, a small molecule inhibitor of the enzymatic activity of BRG1 and BRM for the treatment of metastatic uveal melanoma and relapsed and/or refractory acute myeloid leukemia and myelodysplastic syndrome; and FHD-609, a small molecule protein degrader for BRD9 to treat patients with synovial sarcoma. The company is also developing an enzymatic inhibitor and a protein degrader as selective modulators of BRM; and ARID1B selective modulators for the treatment of ovarian, endometrial, colorectal, bladder, and gastric cancers. It has a research collaboration and license agreement with Merck Sharp & Dohme Corp. to discover and develop novel oncology therapeutics against a transcription factor target; and Loxo Oncology to create novel oncology medicines. Foghorn Therapeutics Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Add to compare list
Add to watchlist
Add to portfolio
Add to notification price

IPO date 2020-10-23
ISIN US3441741077
Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета usd
Сайт https://foghorntx.com
Цена ао 3.81
Change price per day: 0% (3.59)
Change price per week: +11.84% (3.21)
Change price per month: -18.96% (4.43)
Change price per 3 month: -15.33% (4.24)
Change price per half year: -55.73% (8.11)
Change price per year: -40.46% (6.03)
Change price per 3 year: -75.73% (14.79)
Change price per year to date: -27.91% (4.98)
All parameters

Underestimation

Title Value Grade
P/S 8.16 1
P/BV -3.61 0
P/E 0 0
EV/EBITDA -2.45 0
Total: 3.88

Efficiency

Title Value Grade
ROA, % -34.42 0
ROE, % 127.51 10
Total: 3.33

Dividends

Title Value Grade
Div yield, % 0 0
DSI 0 0
Total: 0

Debt

Title Value Grade
Debt/EBITDA -0.4542 10
Total: 10

Growth impulse

Title Value Grade
Yield Revenue, % 7843.02 10
Yield Ebitda, % 109.33 10
Yield EPS, % 0.2094 1
Total: 8
More

Institutions Volume Share, %
Flagship Pioneering Inc. 12674120 29.78
FMR, LLC 2810009 6.6
Raymond James & Associates, Inc. 2068387 4.86
Euclidean Capital LLC 1573761 3.7
Blackrock Inc. 1305868 3.07
Vanguard Group Inc 1025113 2.41
Artal Group S.A. 720720 1.69
Point72 Asset Management, L.P. 540000 1.27
Alphabet Inc. 500901 1.18
Geode Capital Management, LLC 448350 1.05



Head Job title Payment Year of birth
Mr. Adrian H. B. Gottschalk President, CEO & Director 784.65k 1976 (49 years)
Dr. Steven F. Bellon Ph.D. Chief Scientific Officer 572.6k 1965 (60 years)
Mr. Michael J. LaCascia Chief Legal Officer 565.5k 1965 (60 years)
Dr. Gerald R. Crabtree M.d. Founder & Member of Scientific Advisory Board N/A
Mr. Saurabh Sewak Ph.D. Vice President of Corporate Development N/A
Mr. Carlos Costa Chief People Officer N/A 1973 (52 years)
Dr. Alfonso Quintas Cardama M.D. Chief Medical Officer 300.16k 1971 (54 years)
Ms. Karin Hellsvik VP of Corporate Affairs & Investor Relations N/A
Mr. Kristian Humer M.B.A. Chief Financial Officer N/A 1976 (49 years)
Dr. Anna Rivkin Ph.D. Chief Business Officer

Address: United States, Cambridge. MA, 500 Technology Square - open in Google maps, open in Yandex maps
Website: https://foghorntx.com